Shenzhen Shali Biotech Co., Ltd., a global leading cell therapy biotechnology company, today announced the appointment of Dr. Jie Jia as Chief Operating Officer (COO). The above appointments are effective immediately.
Dr. Jie Jia has over 20 years of strategic leadership experience in the healthcare sector, with extensive expertise in managing complex projects, building new businesses, optimizing processes, and guiding key decisions.
Read also – First Phosphate Closes Oversubscribed Private Placement Financing
Prior to joining Shali Bio, Dr. Jie Jia held senior management positions at Coherus Pharmaceuticals and successfully transformed the company from a start-up to a public company by establishing and leading US business operations. Before moving into industry, Dr. Jia served as an assistant professor at Cleveland Clinic and Case Western Reserve University. Dr. Jia holds a Bachelor of Science in Biochemistry from Sichuan University, a Ph.D. in Biochemistry and Molecular Biology from the Chinese Academy of Sciences, a Postdoctoral Certificate in Molecular Medicine from the Cleveland Clinic, and an MBA in Leadership and Digital Marketing from Youngstown State University.
“We are very pleased to welcome Dr. Jie Jia to ShaliBio as the company’s Chief Operating Officer,” said Dr. Yarong Liu, Chairman and CEO of ShaliBio. “His experience in leading biopharmaceutical companies to expand overseas markets and collaborations closely matches ShaliBio’s vision for the international market. We are confident that Dr. Jia’s leadership and expertise will accelerate our mission to develop breakthrough cell therapies for patients with solid tumors worldwide.”
Dr. Jie Jia said, “I am honored to join Shali Bio and work with the company’s team. With an outstanding team of scientists and a cell therapy technology platform with independent intellectual property rights, Shali Bio has made several differentiated TIL projects with great potential and is at the forefront of global development progress. I look forward to further promoting the development and cooperation of these technologies and projects and contributing to the company’s future success.”
About Shali Biotech
Founded in 2019, Shali Biotech is an innovative pharmaceutical company focusing on tumor immune cell therapy, with TIL drugs as its representative R&D pipeline. Shali Biotech has completed multiple rounds of equity financing and has received support from many well-known venture capital funds. GT101 injection, independently developed by Shali Biotech, is the first TIL drug approved for clinical registration in China and is currently entering a key Phase II clinical trial. GT201 injection, the world’s first TIL product with a membrane-bound IL-15 complex, has completed IND filings in China and the United States.
The company’s core R&D platforms include StemTexp® stem TIL amplification technology platform, StaViral® virus – stable strain process, ImmuT Finder® immune regulation target discovery platform, and KOReTIL® efficient gene knockout system, and a series of next-generation gene-edited TIL drugs have been developed based on the platform. Shali Biotech has internationally leading technology reserves and industrial resources, aiming to create groundbreaking solid tumor cell drugs and bring new hope to the majority of cancer patients.
